Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira
This article was originally published in The Pink Sheet Daily
Executive Summary
TAK-652’s potential for once-daily dosing could make it the best-in-class oral CCR5 antagonist, Tobira’s CEO tells “The Pink Sheet” DAILY.